Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Arcadia Biosciences, Inc. Director's Dealing 2015

Sep 26, 2015

35424_dirs_2015-09-25_23ff38c9-080b-423b-a459-10723614669c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Arcadia Biosciences, Inc. (RKDA)
CIK: 0001469443
Period of Report: 2015-09-23

Reporting Person: Rey Eric J. (Director, President and CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2015-09-23 Common Stock M 10826 $0.44 Acquired 10826 Direct
2015-09-23 Common Stock S 4000 $4.8022 Disposed 6826 Direct
2015-09-24 Common Stock M 19095 $0.44 Acquired 25921 Direct
2015-09-24 Common Stock S 7089 $4.3239 Disposed 18832 Direct
2015-09-25 Common Stock M 26971 $0.44 Acquired 45803 Direct
2015-09-25 Common Stock S 10000 $4.027 Disposed 35803 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2015-09-23 Employee Stock Option (right to buy) $0.44 M 10826 Disposed 2015-12-31 Common Stock (10826) Direct
2015-09-24 Employee Stock Option (right to buy) $0.44 M 19095 Disposed 2015-12-31 Common Stock (19095) Direct
2015-09-25 Employee Stock Option (right to buy) $0.44 M 26971 Disposed 2015-12-31 Common Stock (26971) Direct

Footnotes

F1: The security transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Stock Trading Plan (the "Plan"), adopted by the Reporting Person on June 14, 2015. Pursuant to the Plan and in compliance with the Issuer's IPO Lock-up Agreements with Credit Suisse Securities (USA) ("CSSU"), the Reporting Person paid the exercise price and CSSU sold shares only to satisfy the tax liability and costs. The balance of the shares will be held until the expiration of the IPO Lock-up Agreements.

F2: This transaction was executed in multiple trades at prices ranging from $4.61 to $5.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $4.27 to $4.49. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $3.955 to $4.20. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: The option is fully exercisable as of the date hereof.